Compare USLM & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | PBLS |
|---|---|---|
| Founded | 1948 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.4B |
| IPO Year | 1994 | 2026 |
| Metric | USLM | PBLS |
|---|---|---|
| Price | $101.05 | $29.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $138.00 | N/A |
| AVG Volume (30 Days) | 291.9K | ★ 544.5K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 23.22 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $144,435,000.00 | N/A |
| Revenue This Year | $27.25 | N/A |
| Revenue Next Year | $13.76 | N/A |
| P/E Ratio | $93.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $94.77 | $25.56 |
| 52 Week High | $141.44 | $33.65 |
| Indicator | USLM | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 61.19 |
| Support Level | N/A | $26.68 |
| Resistance Level | $114.22 | $30.19 |
| Average True Range (ATR) | 3.98 | 2.45 |
| MACD | -0.61 | 0.27 |
| Stochastic Oscillator | 24.56 | 54.64 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. The company supplies its products predominantly to the construction including highway, road, and building contractors, industrial including paper and glass manufacturers, environmental including municipal sanitation and water treatment facilities and flue gas treatment processes, metals including steel producers, oil and gas services, roof shingle manufacturers and agriculture including poultry industries. The company operates through its Lime and Limestone Operations segment.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.